Supernus Pharmaceuticals, Inc.
supernus.comWhat Do They Do?
Develops and sells medicines for central nervous system diseases, including attention-deficit/hyperactivity disorder, Parkinson’s disease and postpartum depression.
10-K for FY2025, filed Mar 2, 2026Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the…View ↗
Qelbree (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric…View ↗
GOCOVRI (amantadine) extended-release capsules are the first and only FDA-approved medicine indicated for the treatment of dyskinesia in…View ↗
ZURZUVAE® capsules are the first and only FDA approved oral medicine indicated for the treatment of PPD in adults. ZURZUVAE is a…View ↗
How Do They Make Money?
Wholesalers, specialty pharmacies and distributors buy products when they take title, with orders generally fulfilled within a few days; royalty income follows licensed-product sales, while licensing deals can bring upfront fees and milestone payments. Supernus and Biogen share U.S. operating profits and losses from ZURZUVAE sales.
10-K for FY2025, filed Mar 2, 2026The Company's customers are primarily pharmaceutical wholesalers, specialty pharmacies, and pharmaceutical distributors. Customers purchase…View ↗
Royalty revenues include cash royalty amounts received from third parties pursuant to settlement agreements and agreements with…View ↗
The Company's agreements with third parties generally involve the right to use the Company's intellectual property as a functional license.…View ↗
Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Generally…View ↗
both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with…View ↗
-
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗
$719M
-
10-K for FY2025, filed Mar 2, 2026
$719M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
87%
FY2022: 97%
|
Net product sales, FY2025
$626.5M Sources
|
Sold outright |
|
Collaboration revenue (ZURZUVAE)
|
7.4% |
Collaboration revenue (ZURZUVAE), FY2025
$53M Sources
|
|
|
Royalty, licensing, and other revenues
Licensed
|
5.5%
FY2022: 2.7%
|
Royalty, licensing, and other revenues, FY2025
$39.4M Sources
|
Licensed |
Who Are Their Customers?
Pharmaceutical wholesalers, specialty pharmacies and distributors buy most products and resell them to pharmacies, hospitals and other customers. Physicians and hospitals can buy MYOBLOC directly.
10-K for FY2025, filed Mar 2, 2026The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products…View ↗
Do Revenues Turn Into Profits?
Not on paper. It lost $38.6M in FY2025, but brought in more cash than it spent: $46M of free cash flow.
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Oct 29, 2026
$20.9MView ↗
- ▲ Turned profitable
- vs −$45.1M in Q3 FY2025
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
-
Aug 3, 2026
Raised full-year 2026 financial guidance
Sources
8-K, filed Aug 3, 2026
Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the…View ↗
-
Aug 3, 2026
Supernus agreed to merge with Indivior
The proposed deal would make Supernus a wholly owned Indivior subsidiary, subject to stockholder approvals, regulatory approvals and customary closing conditions.
Sources
8-K, filed Aug 3, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will merge with and into the Company…View ↗
Growing. Revenue grew 24% in 4 years, from $579.8M in FY2021 to $719M in FY2025, about 6% a year.
Postpartum depression treatment
The portfolio has added an approved medicine for postpartum depression alongside treatments for its other central nervous system conditions.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 2, 2026Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the…View ↗
Loading...
